Efficacy of an Advanced Auto-titrating NIV in COPD
Clinical Validation, Safety & Efficacy Study of an Advanced Auto-titrating Non-invasive Ventilator in Patients With Severe Chronic Obstructive Pulmonary Disease
Patients with chronic obstructive pulmonary disease (COPD) can eventually progress to respiratory failure, where they cannot adequately exchange oxygen and carbon dioxide, leading to worsening breathlessness, frequent hospitalisations and death. Non-invasive ventilation (NIV) is a ventilator therapy that is used in COPD patients who suffer from respiratory failure. Studies have demonstrated that using NIV at night regularly can result in improved clinical outcomes.
Adherence to this therapy is variable, however. This can be due to poor synchrony between the device and the lungs. A novel ventilator has been designed that delivers NIV but is also incorporated with technology to assess for aberrations in respiratory physiology and correct them, breath-by-breath.
The investigators aim to assess the efficacy, safety and tolerability of this novel ventilator. The primary research question is whether the novel ventilator can improve adherence to therapy, when compared with the usual ventilator.
Patients with COPD who use ventilation at home will be screened for inclusion in the study. Participation will involve a screening visit, and a further two visits to the Lane Fox Respiratory Unit. The first will require a two-night admission and the second a single-night admission. They will undergo detailed assessment of their daytime and overnight respiratory and sleep physiology during these admissions. These visits will be separated by a six-week period during which they will be asked to use the novel ventilator at home.
Patients will be recruited into a sub-study to evaluate the performance of the ventilator in a daytime physiological assessment. This will involve detailed invasive physiological assessment of expiratory flow limitation and how the machine is able to adjust settings to optimise respiratory support.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
London
-
London, London, United Kingdom, SE1 7EH
- Guys and St Thomas NHS Foundation Trust
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Patient Inclusion Criteria:
- Age ≥ 18 years
- BMI <30 kg/m¬2
- Confirmed diagnosis of COPD
- Currently using domiciliary NIV with average reported compliance of at least 3hours
- Ability to provide informed consent
- Medical stability confirmed by recruiting physician
- Free of exacerbations for at least 2 weeks prior to enrolment
- Presence of expiratory flow limitation on forced oscillation technique criteria
Exclusion Criteria:
- Current acute illness as determined by recruiting physician e.g. upper respiratory tract infection
- Presence of major medical comorbidity, e.g. severe heart failure (LVEF <30%), active malignancy, end-stage renal failure (CKD 4), and neuromuscular disease
- Subjects who have had surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days.
- Psychosocial factors that would prevent compliance with study protocol
Healthy participant inclusion criteria:
- Age ≥ 18 years
- No expiratory flow limitation on forced oscillation testing
- No acute illness on study day
- Ability to provide informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Usual non-invasive ventilation
The usual therapy the participant is receiving via non-invasive ventilator.
|
|
|
Experimental: Auto-titrating non-invasive ventilation
A novel auto-titrating non-invasive ventilator
|
A non-invasive ventilator designed to auto-adjust the expiratory positive airway pressure according to expiratory flow limitation, measured using the forced oscillation technique.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adherence to ventilation therapy
Time Frame: 6 weeks
|
Number of hours spent on nocturnal ventilation therapy
|
6 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean nocturnal transcutaneous carbon dioxide level
Time Frame: 1 night during single night admission
|
Mean nocturnal transcutaneous carbon dioxide level measured on single night admission
|
1 night during single night admission
|
|
Maximal nocturnal transcutaneous carbon dioxide level
Time Frame: 1 night during single night admission
|
Maximal nocturnal transcutaneous carbon dioxide level measured on single night admission
|
1 night during single night admission
|
|
Sleep parameters
Time Frame: 1 night during single night admission
|
Sleep efficiency, measured by polysomnography
|
1 night during single night admission
|
|
Sleep parameters
Time Frame: 1 night during single night admission
|
Wake after sleep onset, measured by polysomnography
|
1 night during single night admission
|
|
Sleep parameters
Time Frame: 1 night during single night admission
|
Time in rapid eye movement/non rapid eye movement sleep, measured by polysomnography
|
1 night during single night admission
|
|
Sleep parameters
Time Frame: 1 night during single night admission
|
Apnoea/hypopnoea index, measured by polysomnography
|
1 night during single night admission
|
|
Sleep parameters
Time Frame: 1 night during single night admission
|
4 per cent oxygen desaturation index, measured by polysomnography
|
1 night during single night admission
|
|
Inspiratory capacity
Time Frame: 6 weeks
|
Inspiratory capacity following 6 weeks of each NIV device
|
6 weeks
|
|
Health-related quality of life
Time Frame: 6 weeks
|
Measured using COPD Assessment Test
|
6 weeks
|
|
Health-related quality of life
Time Frame: 6 weeks
|
Measured using Severe Respiratory Insufficiency Questionnaire
|
6 weeks
|
|
Daytime physical activity
Time Frame: 2 weeks
|
Measured using wrist actigraphs during the final 2 weeks of each 6 week arm
|
2 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Neeraj Shah, Guy's and St Thomas' NHS Foundation Trust
- Study Chair: Nicholas Hart, Guy's and St Thomas' NHS Foundation Trust
- Study Director: Patrick Murphy, Guy's and St Thomas' NHS Foundation Trust
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 279564
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease Severe
-
NCT03745547CompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary Disease
-
NCT02103374CompletedSevere Chronic Obstructive Pulmonary Disease
-
NCT05029349RecruitingChronic Obstructive Pulmonary Disease Severe
-
NCT02998515CompletedChronic Obstructive Pulmonary Disease Severe
-
NCT05539547Not yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
NCT07402551RecruitingModerate to Severe Chronic Obstructive Pulmonary Disease (COPD)
-
NCT05431218CompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease Severe
-
NCT02155660CompletedModerate to Very Severe Chronic Obstructive Pulmonary Disease
-
NCT02138916CompletedModerate to Very Severe Chronic Obstructive Pulmonary Disease
Clinical Trials on Auto-titrating non-invasive ventilation
-
NCT05237505RecruitingChronic Obstructive Pulmonary Disease | Obstructive Sleep Apnea | Overlap Syndrome
-
NCT03049982CompletedObstructive Sleep Apnea
-
NCT02551757CompletedStroke | Sleep Apnea, Obstructive
-
NCT03444428CompletedMotor Neurone Disease | Hypoxemia and/or Hypercapnia
-
NCT01210261CompletedSleep Apnea, Obstructive
-
NCT01458444Completed
-
NCT02933112CompletedObstructive Sleep Apnea
-
NCT00251290CompletedTransient Ischemic Attack | Sleep Apnea
-
NCT05022173Active, not recruitingAcute Respiratory Failure